6875 Stock Overview
A biotechnology company, focuses on developing drugs in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Pharmosa Biopharm Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$53.90 |
| 52 Week High | NT$125.50 |
| 52 Week Low | NT$48.25 |
| Beta | 0.57 |
| 1 Month Change | -6.91% |
| 3 Month Change | -24.19% |
| 1 Year Change | -38.05% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 8.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6875 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -0.7% | 1.5% | -0.7% |
| 1Y | -38.0% | 4.6% | 28.8% |
Return vs Industry: 6875 underperformed the TW Biotechs industry which returned 4.6% over the past year.
Return vs Market: 6875 underperformed the TW Market which returned 28.8% over the past year.
Price Volatility
| 6875 volatility | |
|---|---|
| 6875 Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6875 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6875's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 40 | Pei Kan | www.pharmosa.com.tw |
Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016.
Pharmosa Biopharm Inc. Fundamentals Summary
| 6875 fundamental statistics | |
|---|---|
| Market cap | NT$6.96b |
| Earnings (TTM) | -NT$292.93m |
| Revenue (TTM) | NT$50.52m |
137.7x
P/S Ratio-23.8x
P/E RatioIs 6875 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6875 income statement (TTM) | |
|---|---|
| Revenue | NT$50.52m |
| Cost of Revenue | NT$37.10m |
| Gross Profit | NT$13.42m |
| Other Expenses | NT$306.36m |
| Earnings | -NT$292.93m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.27 |
| Gross Margin | 26.57% |
| Net Profit Margin | -579.83% |
| Debt/Equity Ratio | 0% |
How did 6875 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 02:11 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharmosa Biopharm Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|